A new vaccine called Shingrix, approved by Health Canada last in October, and available in January, has been shown in clinical trials to be more than 90 per cent effective at preventing the debilitating nerve pain of shingles in people over age 50.  The Shingrix vaccine is not made with live attenuated zoster virus, as the previous shingles vaccine was – but was created from a protein taken from an inactivated form of the virus, which triggers an immune response in the body, boosted by what’s called an adjuvant. To learn more about it we speak with Dr. Iris Gorfinkel, a family physician/researcher and Andre Picard, a health reporter and columnist at The Globe and Mail.